Filing Flows

Filing Flows › Companies › Lifecore Biomedical › Cash flow

Lifecore Biomedical cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$6.0M in Q1 FY27

Operating cash flow$6.9M
Capital spending−$912K
Free cash flow+$6.0M

Analysis

In Q1 FY27, Lifecore Biomedical generated $6.9M of operating cash flow and spent $912K on capital projects, leaving free cash flow of $6.0M. That is $6.0M more than in Q1 FY26 ($25K).

Operating cash flow was $6.9M against net income of −$40.1M. The largest differences: receivables +$9.7M, contract assets −$2.7M, depreciation & amortization +$2.4M.

Free cash flow

Lifecore Biomedical: free cash flow by quarterLifecore Biomedical: free cash flow by quarter−$4.0MQ1 FY25−$8.6MQ2 FY25−$4.3MQ3 FY25$3.3MQ4 FY25$25KQ1 FY26$3.6MQ3 FY26−$2.7MQ1 FY27$6.0MQ1 FY27
Operating cash flow less capital spending.
Lifecore Biomedical: operating cash flow against capital spendingLifecore Biomedical: operating cash flow against capital spendingOperating cash flowCapital spending−$613K$3.4MQ1 FY25−$6.1M$2.4MQ2 FY25$1.2M$5.5MQ3 FY25$5.3M$2.1MQ4 FY25$1.8M$1.7MQ1 FY26$4.7M$1.1MQ3 FY26−$2.2M$513KQ1 FY27$6.9M$912KQ1 FY27
Latest (Q1 FY27): Operating cash flow $6.9M, Capital spending $912K.

Capital allocation, year by year

Lifecore Biomedical: where the cash came from (up) and went (down), by fiscal yearLifecore Biomedical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY21: Operating cash flow $15.0MFY21: Net borrowing $7.4MFY21: Asset sales $12.9MFY21: Capital spending −$19.3M$35.3MFY21FY22: Operating cash flow −$24.4MFY22: Net borrowing −$55.5MFY22: Asset sales $74.6MFY22: Capital spending −$26.2M$74.6MFY22FY23: Operating cash flow −$17.4MFY23: Net borrowing $3.1MFY23: Shares issued $42.9MFY23: Asset sales $16.7M$62.7MFY23FY24: Operating cash flow $257KFY24: Net borrowing $2.7MFY24: Shares issued $724KFY24: Capital spending −$18.4M$3.7MFY24FY25: Operating cash flow −$206KFY25: Net borrowing −$17.2MFY25: Shares issued $23.9MFY25: Asset sales $7.0MFY25: Capital spending −$13.4M$30.9MFY25
Over these 5 years operating cash flow totalled −$26.8M; the largest uses were capital spending ($77.3M) and net borrowing ($72.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$8.3M
Debt$130M
Net debt$122M
Due within a year$3.4M

Lifecore Biomedical funds itself: free cash flow was — over the last twelve months, and $8.3M of cash and investments stands against $130M of debt ($3.4M due within a year, 2.4× covered by cash).

Lifecore Biomedical: debt maturities by year (FY25)Lifecore Biomedical: debt maturities by year (FY25)$3.4MYear 1$967KYear 2$1.0MYear 3$175MYear 4$1.1MYear 5$7.3MAfter year 5
Principal due in each year as disclosed in the annual report, against $8.3M of cash and investments now.

Where the cash came from and went

Lifecore Biomedical: sources (+) and uses (−) of cash, Q1 FY27Lifecore Biomedical: sources (+) and uses (−) of cash, Q1 FY27Operating cash flow$6.9MCash drawn (+) / kept (−)−$5.8MCapital spending−$912KOther financing−$239KTaxes on employees’ shares−$1K

From profit to cash

Lifecore Biomedical: net income to operating cash flow, Q1 FY27Lifecore Biomedical: net income to operating cash flow, Q1 FY27Net income−$40.1MDepreciation & amortization$2.4MStock-based pay$1.7MOther non-cash−$290KReceivables$9.7MInventory−$2.2MPayables$1.3MAccrued liabilities−$1.2MContract assets−$2.7MPrepaid and other assets$702KOperating cash flow$6.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 FY257717170179
Q1 FY2510419281215

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27$6.9M−$912K——−$5.8M$6.0M
Q1 FY27−$2.2M−$513K——$3.6M−$2.7M
Q3 FY26$4.7M−$1.1M——−$3.3M$3.6M
Q1 FY26$1.8M−$1.7M——$1.4M$25K
Q4 FY25$5.3M−$2.1M—−$8K−$2.9M$3.3M
Q3 FY25$1.2M−$5.5M−$6.0M$17K$4.0M−$4.3M
Q2 FY25−$6.1M−$2.4M−$42K$23.8M−$3.9M−$8.6M
Q1 FY25−$613K−$3.4M$1.9M$1K$2.9M−$4.0M

Lifecore Biomedical: income statement and cash flow

Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%. The chart follows the revenue to costs, profit and cash.

Lifecore Biomedical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.